Long-term Combination Therapy With α-Blockers and 5α-Reductase Inhibitors in Benign Prostatic Hyperplasia: Patient Adherence and Causes of Withdrawal From Medication
Hueih Ling Ong, Chun-Hou Liao, Hann-Chorng Kuo
Int Neurourol J. 2016;20(4):356-362. Published online 2016 Dec 26 DOI: https://doi.org/10.5213/inj.1632526.263
Citations to this article as recorded by 
A prospective, randomized, open‐label, parallel trial comparing the efficacy of α‐blocker or 5α‐reductase inhibitor withdrawal to continued combination therapy on the maintenance of lower urinary tract symptoms in men with benign prostatic hyperplasia
Kwang Suk Lee, Jeong Woo Yoo, Dae Ho Kim, Soyoung Jeon, Juyeon Yang, Byung Ha Chung, Kyo Chul Koo
The Prostate.2024; 84(4): 403. CrossRef
Pharmacological and interventional treatment of benign prostatic obstruction: An evidence‐based comparative review
Sachin Malde, Wayne Lam, Zainal Adwin, Hashim Hashim
BJUI Compass.2021; 2(4): 238. CrossRef
Potential of Moringa oleifera in the Treatment of Benign Prostate Hyperplasia: Role of Antioxidant Defence Systems
Ismail O. Ishola, Kayode O. Yemitan, Olasunmbo O. Afolayan, Charles C. Anunobi, Tobi E. Durojaiye
Medical Principles and Practice.2018; 27(1): 15. CrossRef